Mohsen Hejrati is co-founder and CEO at Clusterone. Prior to founding Clusterone, he was a research engineer at Waymo and senior researcher at Vicarious. At Clusterone, he is focused on large scale machine learning platforms for applications in life sciences and the autonomous vehicles industry. His research interests span computer vision and machine learning. Mohsen has published in IEEE Conference of Computer Vision and Pattern Recognition (CVPR), European Conference on Computer Vision (ECCV) and Neural Information Processing Systems (NIPS) among others. Read his full bio.

Interview with Mohsen Hejrati from Clusterone

Q: What need is Clusterone addressing?

A: AI and machine learning are becoming cornerstone technologies for scientists and engineers, but access to these technologies is still cumbersome. Machine learning – and deep learning in particular – requires lots of computing power, which is challenging to set up and manage. In addition, not all companies have the necessary expertise to apply machine learning and AI. Clusterone helps them solve those complex engineering tasks and takes care of setup, maintenance, and orchestration of the infrastructure behind AI. We enable scientists and engineers to run experiments – even distributed deep learning code – with the click of a button.

A few decades ago, using a computer to do work was really hard, today this has become the easiest thing in the world. We want AI to be the same way. No fiddling around, no complex setup, it should be a tool to get work done, not a time sink.

Q: What are the products and/or services Clusterone offers/develops to address this need? What makes Clusterone unique?

A: We offer the Clusterone deep learning platform – think of it as an operating system for AI – as well as professional engineering and research services through our Applied AI team. Our platform removes the need for infrastructure setup and orchestration. It also allows teams to collaborate on deep learning experiments and easily reproduce previous experiments. Clusterone is an enterprise-grade platform and we work closely with our customers to make sure they get the most out of their AI investments.

The platform is infrastructure-agnostic, meaning it can run on any on-premises cluster or public cloud, as well as integrate into existing workflows. We help teams to use their hardware more efficiently by optimizing cluster utilization and thus saving our customers time and money.

Q: What is your role at Clusterone and what excites you about your work?

A: I am the CEO and co-founder of Clusterone. The AI industry is incredibly fast-moving, and I believe we’re at a crucial turning point where AI moves from labs into mainstream engineering. Being part of this development is very exciting. AI has huge potential for many industries, but precision medicine and biotech stand out in particular. We want to be part of the cure for cancer, aging, and many other pressing problems that we face today. I think that is very exciting.

Q: When thinking about Clusterone and the domain Clusterone is working in, what are some of the recent breakthroughs that are propelling the field forward and how will they impact healthcare?

A: On the hardware side, the biggest breakthrough has been how capable and affordable GPUs and computing power in general has become. Cloud providers make it very simple to access this computing power today, which is a very important step.
When it comes to software, I believe the development of free and open-source resources has been very important. Public datasets and libraries such as TensorFlow and PyTorch make it very easy to get started with AI today.

These developments will have great impact on healthcare through innovative new diagnostic and analysis technologies (e.g. automated cancer cell detection using computer vision). For doctors and hospitals, it is becoming much easier to gain insights from medical imaging and other data they collect. That way, they’re able to help patients more directly and more individually.

Q: What are the short-term challenges that Clusterone and its peers are facing?

A: The market for AI is still young, knowledge about AI, machine learning, and even data science is still not widely available. There’s also a severe talent shortage for AI and machine learning experts. We have to work to educate people about AI and train new talent.

Also, Hardware and Software solutions are evolving at a rapid pace which makes adopting and maintaining any solution especially challenging. At Clusterone, we’re working hard to stay ahead of these developments and to simplify this complexity for our customers by providing a concise user experience across all types of infrastructure.

Q: Is there anything else you would like to share with the PMWC audience?

A: We are excited to see a growing community of life science practitioners focusing on adopting machine learning for the right problems. We see ourselves serving them to build the next breakthroughs in cancer research and personalized medicine.

Interview with Daniel Chen from IGM Biosciences

Q: Checkpoint inhibitors, particularly with PD-L1/PD-1 targeting agents, have benefited a broad range of patients with cancer. How will we improve on this?

A: It’s true that PD-L1/PD-1 inhibitors have led to durable responses in a subset of patients, and survival benefit in many of the patients treated- either as monotherapy or combination.

Read More

Call from PMWC 2019 Silicon Valley Program Committee – We Must Accelerate and Deliver on the Promise of Precision Medicine

Precision medicine advancements are real as demonstrated by the high volume of molecular, “precise” drugs on the market, which are based on extensive molecular and translational understanding of the specific drug targets.

Read More

#AI Play in Patient Diagnosis? How Can We Prepare the Next Generation to Make Sense of Enormous Amounts of Health-related Data?

What role should artificial intelligence play in patient diagnosis? How can we best prepare the next generation to make sense of enormous amounts of health-related data? These were just a few of the questions explored at the 15th Precision Medicine World Conference held at Duke University September 24-25, 2018.

Read More

Interview with Daniella Beller, Manager, Maccabi Research Institute Biobank

Q: What makes the Maccabi Research Institute biobank unique?

A: To explain the uniqueness of the Maccabi Biobank (named “Tipa” in Hebrew which means “drop” or “just a little”), first you must know a little about Maccabi.

Read More

Why We Need Public-Private Partnerships (PPP) To Foster Drug Discovery

Investments in pharma R&D has substantially increased over the last decades. Yet there appears to be no clear correlation to the number of newly approved drugs. This fact is accompanied by ever-increasing healthcare costs, fueled by an aging population and the parallel rise in the chronic disease burden.

Read More

Precision Medicine: A Decade of Improving the Standard of Care

In January, PMWC will host its 2019 Silicon Valley event, the largest Precision Medicine conference in the world with over 2,500 attendees gathering at the Santa Clara Convention Center. We are humbled and honored to have reached this stage of growth and are looking forward to continuing our work with key stakeholders and decision makers across the industry to ever strengthen this forum for exchange of critical and timely topics, to move the field of precision medicine forward and to improve the Standard of Care.

Read More

Interview with David Hong from Karius

Q: What need is Karius addressing?

A: Physicians often have difficulty pinpointing the exact pathogen that is causing disease. Conventional diagnostics like blood cultures or PCR can have poor sensitivity due to pretreatment with antibiotics, the breadth of potential pathogens present, and the requirement for invasive procedures to access deep-seated infections.

Read More

Interview with Charles Jaffe, MD, PhD from HL7

Q: What need is HL7 addressing?

A: For more than three decades, HL7 has provided the platform to enable global health data interoperability. This is more important than ever, as the cost of healthcare has increased exponentially, and the complexity of clinical evidence has grown to an almost unmanageable state.

Read More

Interview with Eden Haverfield from Invitae

Q: What need is Invitae addressing?

A: Our mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae is uniquely positioned to answer some of life’s most serious and complex questions with the highest quality genetics and at an affordable price.

Read More

Call by Ralph Snyderman (Duke U.) for Big Changes to Get to the Next Level of Precision Medicine

Beyond next-generation gene sequencing and developing diagnostic tools and targeted therapies, theoverall approach to clinical care has to be re-envisioned to fulfill the promise of precision medicine. Care must move from sporadic treatment of episodic disease (a reactive mode) to predicting disease and then acting to prevent and mitigate it (a proactive mode).

Read More

Interview with William Hearl From Immunomic Therapeutics, Inc.

Q: What need is Immunomic Therapeutics, Inc. addressing?

A: Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory.

Read More

Interview with Ralph Snyderman from Duke University

Q: What are some of the critical contributions that academic institutions and medical centers are making to implement and accelerate precision medicine?

A: Over the past decade, the field of precision medicine has created technologies enabling far more personalized and effective health care delivery. Many of the most dramatic advances have come in the field of oncology but targeting care to the needs of the individual is rapidly achieving broader applications.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 16th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 20-23, 2019. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!
pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!